Glaukos price target raised to $113 from $108 at Needham

Needham raised the firm’s price target on Glaukos to $113 from $108 and keeps a Buy rating on the shares. The company’s Q1 revenue beat was driven by iStent infinite, though the management expects the majority of the iDose revenue contribution for the year to come in the second half of 2024 as reimbursement codes become effective and as more doctors are trained on the procedure, the analyst tells investors in a research note.